However, mutations in core upstream regulators of the Hippo pathway in cancers where YAP/TAZ activity is high are surprisingly infrequent, suggesting other mechanisms leading to the stabilisation of YAP/TAZ may be more important in these contexts [1]. The gene discussed is YAP1; the disease is cancer.